November 18th, 2026FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast CancerAn oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer. Read more
November 18th, 2026Hepatitis B Screening Gaps Persist as Functional Cure Option ArrivesNew York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.Read more
November 18th, 2026Dazodalibep Shows Phase 3 Benefit in Sjögren Disease Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.Read more
November 18th, 2026IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New DrugsSan Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.Read more
November 18th, 2026Obstructive HCM Care Hinges on Teams, Pharmacy, and Drug Access Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM treatment.Read more
November 18th, 2026FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMRThe FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.Read more
November 18th, 2026MASH Drugs Raise Urgency for Earlier Diagnosis: Rohit Loomba, MDEarlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.Read more
November 17th, 2026Atopic Dermatitis Escalation Stalls on Payer Rules, Thin TrackingSan Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.Read more